BridgeBio posted $180.6 million in U.S. Attruby net product revenue in Q1 2026 — a single drug, launched roughly 18 months ago, now generating a run rate that most rare-disease franchises never reach. The more strategically consequential number, though, is $500 million: the share repurchase authorization the board quietly tucked alongside the earnings release. A company sitting on $940 million in cash and staring down three near-term NDA submissions doesn’t authorize a buyback of that size because it’s being conservative. It does so because management believes the market is systematically mispricing what comes next.
The real-world evidence accumulating around acoramidis is the mechanism by which that mispricing gets corrected. A medRxiv analysis showing a 43% reduction in diuretic intensification versus tafamidis isn’t a soft signal — diuretic escalation is a proxy for disease progression and hospitalization risk, and payors understand it. A separate independent study presented at SCAI showing statistically significant outcome improvements compounds the pressure on tafamidis’ market position. Pfizer’s drug has had years of post-approval dominance and a deeply embedded prescribing base. BridgeBio is not chipping away at the margins anymore; it is building a durable evidence moat that makes switching conversations structurally easier for cardiologists and formulary committees alike.
Layered on top is the pipeline optionality that the market appears to be discounting entirely. Three NDAs — BBP-418 in LGMD2I/R9, encaleret in ADH1, and oral infigratinib in achondroplasia — are either submitted or on track for submission within the next two quarters, all with potential priority review eligibility. Commercial teams are already assembled for each indication. BridgeBio is not building toward launches; it is pre-positioned for them, with the Attruby commercial infrastructure providing both a cash engine and an operational template. That combination — a profitable anchor asset funding a three-product launch wave — is structurally rare in biotech and rarely valued correctly in real time.
The single number to track is Attruby’s treatment-naïve patient share in the next two quarters. Strength there signals that cardiologists are defaulting to acoramidis as a first choice rather than a switch option, which resets the ceiling on peak revenue estimates and directly validates the buyback’s underlying logic.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
